CAMBRIDGE, England, April 22, 2013 /PRNewswire/ --
Kymab, a monoclonal antibody biopharmaceutical company, announced today an agreement in therapeutic antibody discovery. Novo Nordisk has been granted a non-exclusive licence to Kymab's proprietary Kymouse™ human antibody discovery platform to discover, develop and commercialise therapeutic monoclonal antibody drugs for human diseases.
The licence provides Novo Nordisk with access to the Kymouse HK and Kymouse HL transgenic human antibody mouse strains, which can generate highly selective, potent, human antibody drug candidates. The Kymouse HL strain produces antibodies with human heavy and lambda light chains whereas Kymouse HK generates antibodies with human heavy and kappa light chains. By using these strains in combination, a diverse pool of human antibodies can be created with both classes of light chains fully represented.
Dr. Tom Shepherd, Chief Business Officer of Kymab, said: "Novo Nordisk's expertise and track record in developing biological therapeutics coupled with its existing therapeutic antibody discovery infrastructure makes it an ideal partner for Kymab. Our strategy is to partner the Kymouse platform broadly to maximise its potential in the discovery and development of new medicines."
Hanne Risager Romedahl, Vice President, Head of ImmunoTechnology, Novo Nordisk, said "Antibody therapeutics have great potential to advance patient care in diseases with significant unmet medical need. Kymab's highly innovative and technically advanced Kymouse platform is an excellent fit with our existing therapeutic antibody discovery capability."
The financial terms of the agreement were not disclosed, but include platform licence fees, development milestone payments for drug candidates and royalties on sales of antibodies discovered using the Kymouse strains.
Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse™ transgenic antibody platform.
Kymouse™ has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in-class characteristics.
Founded in 2009, Kymab raised £20m of equity financing in 2010 from the investment division of the Wellcome Trust. It has an experienced management team with a successful track record in drug discovery and development.
For further information, please visit http://www.kymab.com
About Novo Nordisk
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 35,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.com.
Kymab, Kymouse, Kymouse HK and Kymouse HL are trademarks of Kymab Limited.
Dr. Tom Shepherd, Chief Business Officer
Tel: +44(0)1223-833301, Email: firstname.lastname@example.org
Tel: +44(0)20-7920-2361, Email: email@example.com